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Summary Small size inocula (101-103 cells) of cells from a syngeneic methylcholanthrene-induced fibro-
sarcoma (FSA) induced tolerance when injected s.c. into C3Hf mice. Mice were unable to respond to
subsequent challenge with moderate, immunogenic doses of FSA. Tolerance was demonstrated in an in vivo
transfer (Winn) assay and an in vitro tumour-specific TH cell assay. Low zone tolerance was associated with
the presence of tumour-specific Ts cells in the spleen.
Moderate size inocula (104-106 FSA cells) were immunogenic but larger cell doses (>106) were again
tolerogenic. In the high zone, tolerance was associated with both tumour-specific Ts cells and non T
suppressor cells that were not tumour-specific.
These results support the view that immunogenic tumours, as they grow from small cell numbers, might be
able to escape host surveillance by specifically tolerizing the immune system. They also suggest that large
tumour burdens can interfere with the host's immune response by inducing suppressor cells.
An important concept in tumour immunology is
that tumours grow only if they can avoid host
immune responses. An extension of this concept is
that immune responses are selective forces during
tumour progression. Numerous mechanisms have
been envisaged and investigated by which tumours
could escape immune defences. Early research re-
volved around lack of immunogenicity of tumours,
shedding and modulation of cell surface antigens
and blocking of tumour reactive lymphocytes by
antigen-antibody complexes (Hellstrom &
Hellstrom, 1969). More recent studies take into
account our knowledge that the immune system is
composed of complex interacting and self-regulating
networks of cells and soluble factors and have
focused on whether antigens on progressor tumours
have properties that allow them to avoid protective
immunity, for example by preferentially stimulating
suppressor cell circuits (Moser et al., 1983; Greene,
1980; Fujimoto et al., 1976; Reinisch et al., 1977;
Frost et al., 1982; Kolsch et al., 1973; Mengersen et
al., 1975; North, 1984; Haubeck & Kolsch, 1982).
The ability of many tumours to stimulate Ts
has been established although the conditions under
which they are generated and the extent to which
they facilitate growth of primary tumours still re-
quires clarification. In our previous studies with a
transplantable murine fibrosarcoma (FSA) we
found both tumour-specific Ts and non-tumour-
specific non-T suppressor cells in the spleens of
tumour-bearing mice in the later stages of tumour
growth (Howie & McBride, 1982; McBride &
Howie, 1984). The tumour grew initially in the face
of developing systemic responses that were demon-
strably protective. Concomitant immunity (Milas et
al., 1982) and tumour-specific responses could be
demonstrated by both in vitro (Howie & McBride,
1982; McBride & Howie, 1984) and in vivo (Peters
et al., 1978; McBride et al., 1980) assays. Suppres-
sor cells did, however, appear to act in time to
prevent tumour regression and to facilitate late
metastatic spread. The development of Ts cells
under such conditions has been described by many
and most extensively investigated by North and
colleagues (North, 1984). These studies, however,
shed little light upon mechanisms operating during
the initial stages of primary tumour growth which
is presumably the most important period in terms
of tumour escape.
In previous experiments we assessed only the
response to FSA tumours growing from moderate-
size inocula (4 x 105 cells). We subsequently varied
the initial tumour load so as to build up a more
complete picture of the host-tumour relationship. In
this paper we show that both small (101-103 cells)
and large (107 cells) size tumour inocula induce Ts
cells and tolerance and only moderate size inocula
induce immunity. This is therefore analogous to the
classic two-zone tolerance phenomenon seen with
certain soluble antigens (Mitchison, 1964).
Induction of low zone tolerance by methylcholan-
threne-induced cells confirms and extends the find-
ings of Kolsch and coworkers (Kolsch et al., 1973;
Mengersen et al., 1975; Haubeck & Kolsch, 1982)
in other tumour systems. They have investigated in
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detail the Balb/c plasmacytoma ADJ-PC-5 and
have shown that when irradiated plasmacytoma
cells are injected in initially low but exponentially
increasing doses, the first immunological reaction is
Ts cell activation which can prevent in vitro Tc cell
generation. This phenomenon could explain how
immunogenic tumours grow in the first place.
Tumours growing naturally from one or a few cells
might, in the early stages of tumour growth, induce
tumour-specific Ts which would facilitate escape
from immune surveillance. This is a non-mutually
exclusive alternative to the more common explana-
tion that the agents used to induce such tumours
are generally immunosuppressive (Stutman, 1975).
As pointed out by Kolsch, it could also explain the
propensity some tumours have for growing just as
readily, if not more readily, from low as from
moderate cell doses - the phenomenon of 'sneaking
through' (Old et al., 1962).
Materials and methods
Mice
C3Hf/Sed//Kam female mice were used. They were
about 12 weeks of age at the start of the experi-
ment.
Tumour
The methylcholanthrene-induced syngeneic fibro-
sarcoma (FSA) used in these experiments has been
described in detail previously (Howie & McBride,
1982; McBride & Howie, 1984; Milas et al., 1982;
Peters et al., 1978; McBride et al., 1980). It had
been transplanted 7-9 times when used. Tumour
cell suspensions were made as described (Howie &
McBride, 1982; McBride & Howie, 1984).
Experimental design
The aim of these experiments was to examine the
effect of varying doses of FSA upon the immune
response. Preliminary experiments established that
4 x 105 cells s.c. gave a strong response which
peaked 7 days after challenge (Howie & McBride,
1982). Less than 104 cells gave no response while
greater than 106 cells were also less effective. Vary-
ing doses of FSA were injected s.c. into the right
flank followed 10 days later by 4 x 101 cells into the
left flank. Spleens were removed one week later and
their anti-tumour activity assayed.
Winn assay
T cells were enriched from spleen suspensions by
passage over nylon wool columns (Howie &
McBride, 1982). Cells were mixed with 2 x 104
viable FSA and injected s.c. into 40 sites in 20
recipient mice per treatment (Peters et al., 1978;
McBride, et al., 1980). Sites were palpated for
tumour growth. The day 21 results are reported
which is the first day when all control sites were
100% positive. The results represent data from two
separate experiments.
TH and Ts cell assay
These assays have been published (Howie &
McBride, 1982; McBride & Howie, 1984). In brief,
2.5 x 106ml- spleen cells from mice primed with
trinitrophenylated calf red cells were treated with
anti-Thy 1.2 and complement and used as a B cell
source in all cultures. Spleen (105 ml) cells from
tumour-bearing mice were treated as described in
the text and were the source of primed T cells.
Lethally irradiated (50Gy) TNP-FSA cells
(104ml-1) were the source of antigen. Cultures of
admixed T cells, B cells and antigen, with appro-
priate controls, were established in triplicate. The
TH cells are the limiting factor in these assays.
Anti-TNP responses were measured on day 5 by
indirect plaquing with TNP-SRBC as antigen.
Putative suppressor cells were added at 105 cells
ml-1 to cell cultures known to be capable of
responding i.e. containing splenic T cells from mice
receiving 4 x 105 FSA s.c. 7 days previously.
Specificity or non-specificity of suppression was
assayed by examining the ability of the putative
suppressors to inhibit responses of T cells taken
from TNP-CRBC primed mice with TNP-CRBC as
antigen (Howie & McBride, 1982; McBride &
Howie, 1984).
The anti-Thy 1.2 used was monoclonal 30:H: 12
which was a kind gift of Dr Micklem, Department
of Zoology, Edinburgh University.
Results
We used two assays to measure tumour-specific
responses. The first was a Winn assay in which
nylon wool, non-adherent spleen cells from mice
were mixed with viable tumour cells and injected
s.c. into normal recipients (Peters et al., 1978;
McBride et al., 1980). Immunity is dependent upon
primed Lyl+2- cells and is immunologically specific
(McBridge & Howie, unpublished). The develop-
ment of immunity in mice receiving standard
inocula of tumour cells was prevented by prior
inoculation of either low (101-103) or high (greater
than 106) doses of the same tumour (Figure 1).
Because the Winn assay is not very well-suited to
subpopulation analysis we turned to a sensitive in
vitro assay for tumour specific TH cell activity
(Howie & McBride, 1982; McBride & Howie, 1984)
to analyze this phenomenon further. The kinetics ofTWO-ZONE TOLERANCE TO A MURINE FIBROSARCOMA
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Figure 1 Two zone tolerance to FSA as measured by
the Winn assay. Mice were pretreated with varying
doses of FSA by injecting them into one flank. Ten
days later 4 x 105 FSA cells were injected into the
opposite flank. After a further 7 days, splenic T cells
were isolated, admixed with viable FSA cells at a 33: 1
ratio and recipient mice were injected with inocula
containing 2 x 104 FSA per site. The percentage of
positive sites on day 21 is shown, a time when all
control sites receiving FSA alone or normal T cells
plus FSA, were positive.
responses demonstrated using this assay have previ-
ously been shown to parallel closely those of the
Winn assay (Howie & McBride, 1982; McBride &
Howie, 1984). The TH assay relies on the recogni-
tion in vitro of tumour-specific determinants on
irradiated trinitrophenylated tumour cells by TH
cells and presentation of TNP to B cells to generate
an anti-TNP response. As can be seen in Figure 2
as few as l0'-l03 viable FSA cells prevented the
development of tumour-specific TH cell activity in
the spleens of mice subsequently challenged with
4 x 105 cells. Greater than 106 cells had a similar
effect. Between these two zones immunity
developed.
In both low and high dosage zones, suppressor
cells developed (Figure 2). Spleen cells from these
mice could inhibit anti-tumour responses of spleen
cells from mice receiving only tumour challenge.
Low zone suppressor cells were tumour-specific Ts
cells in that they were Thy 1.2 positive (Figure 2)
and did not suppress anti-CRBC TH cell responses
(Figure 3). High zone suppressor cells contained
tumour-specific and non-tumour-specific cells in
that whole spleen cells suppressed anti-CRBC and
anti-FSA TH cell responses (Figure 3) whereas
nylon wool-passed cells only suppressed anti-
tumour responses (Table I). This is a similar result
to that already found in mice bearing large tumour
burdens (Howie & McBride, 1982; McBride &
Howie, 1984).
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Figure 2 Two zone tolerance to FSA as measured by
the TH cell assay. Mice were treated in an identical
fashion as for Figure 1 except the level of tumour-
specific T cell help within the spleen cell populations
was measured as described in Materials and methods.
The control 100% value represents the PFC response
generated by spleen cells from mice receiving 4 x 105
FSA cells only (no pretreatment). The effect of pre-
treatment with various doses of FSA is shown (A-A).
The possibility that suppressor cells were responsible
for the decreased responses by some of the pretreated
groups was tested for by mixing spleen cells from these
groups with spleen cells from control mice receiving
only challenge with FSA (100% group). Suppressor
cells were present where there was decreased
responsiveness([ ]El).Treatmentwithanti-Thy 1.2plus
complement abolished suppressor cells only in the low
zone groups (0 0).
Table I Suppression of anti-FSA and anti-CRBC
responses by T cells from high zone tolerant mice.
Percent suppression
FSA response CRBC response
Whole spleen 98 95
Nylon wool
nonadherent cells 96 25
Nylon wool nonadherent spleen cells and non-separated
cells from mice receiving 107 FSA s.c. followed by
challenge with 4 x 105 FSA as in Figure 1 were tested for
their ability to suppress anti-FSA and anti-CRBC
responses as in Figures 2 and 3.
Discussion
We have shown that this immunogenic fibro-
sarcoma can induce two zones of immunological
tolerance in normal mice. As few as 101-103 viable
cells can induce low zone tolerance while 105-106
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Figure 3 The specificity of suppressor cells generated
by low and high doses of FSA. The ability of spleen
cells from mice pretreated with varying doses of FSA
and challenged with 4 x 105 FSA cells as in Figure 1 to
suppress the generation of TNP-CRBC responses was
tested. The 100% value represents responses of
separated T and B cell populations from TNP-CRBC
primed mice with TNP-CRBC as antigen. Non-specific
suppressor cells were present only in the high dose
groups.
cells stimulate powerful responses. Larger cell doses
induce high zone tolerance which is associated with
a more complex and more generalized state of
immunosuppression. This last state is probably re-
sponsible for the marked loss in immunity when
this tumour grows large and may allow metastases
to develop (Milas et al., 1974).
Low zone tolerance may account for several
aspects of tumour behaviour. One of these is
'sneaking through' (Kolsch et al., 1973; Mengersen
et al., 1975; Haubeck & Kolsch, 1982). One would
predict that for 'sneaking through' to be explained
on this basis there would have to be a dose window
where tumour take is inibited by the development
of immunity but this manifestation of immunity can
be masked by larger tumour cell numbers. Below
this window tolerance would be induced. Further-
more to see 'sneaking through', the transplanted
tumour must be sufficiently resistant to natural
immune mechanisms and sufficiently clonogenic to
grow from cell doses that induce tolerance. These
requirements would explain why 'sneaking through'
is not seen with all tumours and opens up the
possibility that low zone Ts cell induction may be a
more general phenomenon.
It is possible that tumours, even ones capable of
inducing immunity, might have initially escaped the
attentions of the host immune system by inducing
tolerance. It would be interesting to study the
highly immunogenic UV-induced tumours in this
regard. It should be noted that, with the possible
exception of certain virus-coded products, there is
no compelling reason to consider tumour antigens
as being anything other than self or minimally
altered self components, perhaps exceptional only in
the amount and timing of their expression. One
might expect responses to such antigens to be under
close suppressor cell control. Under natural con-
ditions anti-tumour responses might therefore re-
quire breakage of a tolerant state and could be
considered as largely autoimmune in nature.
Finally, we previously noted that immunotherapy
of this tumour with C. parvum was only effective
when inocula of moderate size were used (Peters et
al., 1978). Not only were small-size inocula not
rejected but tumour take was actually enhanced.
We can now explain the lack of effect of C. parvum
on small size inocula as being due to the presence
of a tolerant state.
These studies reemphasize the need for extreme
care when drawing conclusions from experiments
where single doses of transplanted tumours are
used and suggest that tolerant mice might be a
useful tool for studying the effects of the immune
system and immuno-therapy on tumour behaviour.
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